U.S. imports of Antimalarial Medicaments in Measured Doses for Retail Sale (HS 300460) totaled $204K in August 2026, imported from 7 countries.
Antimalarial Medicaments in Measured Doses for Retail Sale imports of $204K in August 2026 ran 37% below the year-to-date monthly average of $326K.
Last updated: August 2026 dataFinished-dose antimalarial preparations whose active ingredients are defined by Subheading Note 2 to Chapter 30 are classified under tariff line 3004600000. This heading was introduced in the HS 2017 revision to separately track artemisinin-based combination therapies (ACTs) and other priority antimalarials, reflecting global public health policy goals around access to these medicines. FDA regulates imported antimalarial drug products through its standard drug approval and foreign establishment registration framework, and importers should verify that the specific active ingredient qualifies under the applicable subheading note rather than defaulting to the residual 300490 heading. Supply chains for antimalarials often involve manufacturers in Asia, and importers should confirm that foreign establishments are on FDA's approved list prior to shipment.
AI-written summary of the official U.S. Census Bureau trade figures on this page — verify before relying on it.
4 import shipments a month
Classification in 300460 requires that the active antimalarial substance be one of those specifically enumerated in Subheading Note 2 to Chapter 30. Artemisinin derivatives and certain combination therapies are the primary targets of this note. If the active ingredient is not listed in that note, the product falls to the residual heading 300490. Importers should review the current Subheading Note text and consult a licensed customs broker to confirm eligibility.
Antimalarial medicaments are not broadly subject to Section 301 or antidumping measures as a category, but duty treatment can vary by country of origin. Importers should verify the current tariff schedule and any applicable trade-remedy orders for the specific country of manufacture, as pharmaceutical supply chains frequently involve multiple countries for API sourcing and finished-dose manufacturing. Consult a licensed customs broker for origin determination and admissibility review.
Subheading 11 of 12 in heading 3004
Subheading 300460 · $204K of $7.1B
ImportsExports
Imports
$204KYoY · free account
Exports
$242KYoY · free account
Low of 11 reported months · imports
Low · free accountOver the twelve months to August 2026, the U.S. exported $1.6M of Antimalarial Medicaments in Measured Doses for Retail Sale.
Fewer than 6 of the last 12 months reported trade, or the latest month was under $500K; the trend chart is not shown for thin series.
Through August 2026 · imports 11 of 12 months reported, exports 11 of 12 months reported. Source: U.S. Census Bureau.
Trade Directory
List your company under HS 300460 — Antimalarial Medicaments in Measured Doses for Retail Sale, so the companies trading it can find you. Be the first supplier listed.
HS10 import codes under this HS6 parent, each with its own page. Source: U.S. Harmonized Tariff Schedule.
| Code | Description | Imports for consumption | Average duty rate | Dutiable Share |
|---|---|---|---|---|
| 3004600000 | Other Meds, Antimalarial in Subh Note 2, Measured | $204K | 0.00% | 0.00% |
HS10 export codes under this HS6 parent, each with its own page. Source: U.S. Schedule B export classification.
| Code | Description | Export Value |
|---|---|---|
| 3004600000 | Other Meds, Antimalarial in Subh Note 2, Measured | $242K |
Import lines come from the U.S. Harmonized Tariff Schedule and export lines from Schedule B. The two are numbered by different agencies, so the same 10-digit code can appear in both tables describing a different product.
Imports · August 2026
origin
India and China together supply 98% of it.
customs district
destination
entry
rate provision · imports
100.0% enters free of duty; duty collected equals 0.00% of imports for consumption.